Genmab to acquire Merus for $8 billion in all-cash deal
PositiveFinancial Markets

Genmab's recent decision to acquire Merus for $8 billion in an all-cash deal marks a significant move in the biotech sector. This acquisition not only strengthens Genmab's portfolio but also highlights the growing trend of consolidation in the pharmaceutical industry. By bringing Merus's innovative therapies under its wing, Genmab aims to enhance its research capabilities and expand its market reach, which could lead to groundbreaking advancements in cancer treatment.
— Curated by the World Pulse Now AI Editorial System